The Massachusetts attorney general joined that federal lawsuit accusing Johnson & Johnson of paying kickbacks to push the antipsychotic Risperdal and other drugs into nursing homes. AG Martha Coakley didn’t stop there; however, her office is also investigating other companies that market antipsychotics to nursing homes in the state.
Federal prosecutors alleged that Johnson & Johnson paid one of the nation’s largest pharmacies serving nursing homes “tens of millions of dollars in kickbacks” to increase sales of drugs including blockbuster antipsychotic Risperdal.
AstraZeneca paid Chicago psychiatrist Dr. Michael Reinstein $490,000 over a decade to travel the nation promoting its best-selling antipsychotic drug, Seroquel. In return, Reinstein provided the company a vast customer base: thousands of residents in Chicago-area nursing homes.
The U.S. Justice Department said that Johnson & Johnson’s kickbacks to Omnicare, the largest U.S. provider of pharmacy services to nursing homes, took multiple forms, including rebates that were conditioned on Omnicare engaging in an ‘Active Intervention Program’ for Risperdal and payments disguised as data purchase fees, educational grants, and fees to attend Omnicare meetings.
Psychiatrists’ increasing reliance upon involuntary commitment in psychiatric facilities and forced mental health treatment has caused a litany of harm and human rights abuses—funded by…